The effect of tumor necrosis factor (TNF) in combination with thymosin and chemotherapy on advanced primary liver cancer was observed. Eighty-nine advanced primary liver cancer cases were randomized into two groups: Patients in the control group were treated only with chemotheraputic drugs, and patients in the observing group were treated with TNF, thymosin and chemotheraputic drugs. The results showed that there were higher primary tumor regression rates and statistically reduced AFP in the observing group than control group. The rate of half year survival, one year survival and two years survival improved 28.6%, 18.0% and 5.1% than those of control group, respectively. We belived that this combined therapy could effectivelly improve the patients immunity, the quality of survival, and long the patients survival period.